Abstract C134: Trends in prostate cancer disparities among diverse populations in Philadelphia

Background: Prostate cancer (PCa) is a leading cause of cancer morbidity and mortality in the US. There are profound differences in PCa outcomes by race/ethnicity and socioeconomic status. Over the last 15 years, PCa screening recommendations have changed, potentially influencing recent trends. To examine racial/ethnic differences in PCa incidence, stage at diagnosis, and mortality, we conducted statistical analyses focused on the diverse patient population of Philadelphia, Pennsylvania (PA). Methods: Early (stages I-II) and late-stage (stage IV and on) PCa incidence and mortality age-adjusted rates (per 100,000) from 2007-2022 were obtained from the PA Data Dissemination Informatics Exchange (EDDIE) for Philadelphia County. We calculated incidence rate ratios to measure disparity and compared percent change over time for patients of each major racial/ethnic group: Asian/Pacific Islander (API), Black, Hispanic, and White using PCa incidence rates. When used, “All Races” refers to Blacks, Whites, Asians, and Hispanics collective data. Disparity ratio measures compared the first year (2007 & 2008) to the most recent year (2021 & 2022) of mortality, early, and late-stage PCa. White PCa patients were used as the baseline for comparison. Some stage-related data were available only for larger population racial/ethnic subgroups. Results: 15,798 incident PCa cases were diagnosed in Philadelphia from 2007-2021. The patient composition was 47.7% Black, 35.5% White, 4.8% Hispanic, 1.8% API, and 10.2% other/unknown race. Findings showed higher PCa incidence for Black men compared to Non-Black populations, while rates were lowest for API. Early PCa incidence decreased in All Races (-49%), Black (-44%), Hispanic (-28%), and White (-39%). Late-stage PCa incidence increased in All Races (14%), Black (7%), and White (9%) patient populations. Mortality rates decreased for Black (-30%) and White (-44%) populations, and among All Races (-34%). For early-stage PCa, rate ratios varied from 2007 to 2021. Black patients decreased from 2.1: 95% C.I. (1.81, 2.39) to 1.55 (1.24, 1.91) risk of early-stage PCa diagnosis compared to White patients, whereas Hispanic patients increased only slightly from 0.88 C.I. (0.7, 1.1) to 0.89 (0.66, 1.12). For late-stage, Black patients showed a slight decrease in comparative risk going from 2.0 C.I. (1.4, 2.8) to 1.96, the C.I. showed no change. For mortality, Black men showed a noticeable increased risk, 2.34 C.I. (1.77, 3.14) to 2.92 (2.03, 4.06) when compared to White men. Conclusions: PCa disparities persist, particularly for mortality rates among Black men within Philadelphia. Interestingly, recent trends suggest an increasing risk of late-stage diagnosis for all men, which also requires further attention. Analyzing PCa rates, particularly across intervals encapsulating updated preventive guidance, can help us better understand what further interventions are needed within local communities. Citation Format: Oluwademilade Adefarati, Scott W. Keith, Rickisa Yearwood, Jenna R. Hoopes, Ann Klassen, Kevin Henry, Daniel Wiese, Edouard Trabulsi, Charnita Zeigler-Johnson. Trends in prostate cancer disparities among diverse populations in Philadelphia [abstract]. In: Proceedings of the 18th AACR Conference on the Science of Cancer Health Disparities; 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr C134.